Inclusion Criteria:

- Histologically or cytologically confirmed, advanced (stage IIIB with pleural
effusion, stage IV, or recurrent), kras mutation positive, non-small cell lung cancer
(NSCLC)

- Measurable disease per RECIST criteria

- Patients must have received one + prior chemotherapy regimens for NSCLC

- Patients may have treated and clinically stable brain metastases

- Adequate bone marrow, liver and renal function

- Women of childbearing potential must have a negative serum pregnancy test within 7
days prior to the start of treatment

- Women of childbearing potential and men must agree to use adequate contraception
(barrier method of birth control) prior to study entry and for the duration of study
participation, and for 3 months after last administration of sorafenib

- Patients must have the ability to understand and willingness to sign a written
informed consent

- International normalized ratio(INR) < 1.5 or prothrombin time/ partial thromboplastin
time (PT/PTT) within normal limits

Exclusion Criteria:

- Prior exposure to a Ras pathway inhibitor

- Any other anti-tumor therapy within 3 weeks of enrollment

- Prior bevacizumab within the past 6 weeks

- An active secondary malignancy except non-melanoma skin cancer

- Cardiac disease: Congestive heart failure > class II NYHA. Patients must not have
unstable angina or new onset angina or myocardial infarction within the past 6 months

- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

- Uncontrolled hypertension, defined as systolic blood pressure > 150mm Hg or diastolic
pressure > 90mm Hg, despite optical medical management

- Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C

- Active clinically serious infection > Common Terminology Criteria for Adverse Events
(CTCAE) Grade 2

- Thrombolic or embolic events such as cerebrovascular accident including transient
ischemic attack within the past 6 months

- Pulmonary hemorrhage/bleeding event >/= CTCAE Grade 2 within 4 weeks of first dose of
study drug

- Any other hemorrhage/bleeding event >/= CTCAE Grade 3 within 4 weeks of first dose of
study drug

- Serious non-healing wound, ulcer, or bone fracture

- Evidence or history of bleeding diathesis or coagulopathy

- Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
study drug

- Use of St. John's Wort or rifampin

- Known or suspected allergy to sorafenib or any agent given in the course of the trial

- Any condition that impairs patient's ability to swallow whole pills

- Any malabsorption problem